What is Skinvisible Inc?
focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas.
SKVI · Verdict
Limited reward · high risk
SKVI has limited near-term tailwinds — balance sheet and cash flow weigh on the model output.
Based on 88% data coverage
SKVI · Verdict
Current ratio 0.01
-395% free-cash-flow margin
Rev -68.9% CAGR · earnings -19.2%
Weak vs peers
Below average
-2828% net margin · 0% ROE
Model-based scoring. For information only — not financial advice.
focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company is listed on the OTCQB in USA, operating in the Consumer Defensive sector, with a market capitalisation of 2.03M.
The scoring profile indicates weak reward characteristics across most factors, including momentum and size. Risk indicators are high — this profile reflects meaningful downside exposure.
For informational purposes only. Not financial advice.